IMNM Immunome Inc
Price (delayed)
$8.52
Market cap
$740.82M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5
Enterprise value
$602.14M
Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics that are designed to change the way diseases are
Highlights
IMNM's EPS is up by 38% QoQ and by 7% YoY
IMNM's net income has dropped by 174% year-on-year but it is up by 4.1% since the previous quarter
The equity has soared by 51% YoY but it has contracted by 16% from the previous quarter
IMNM's debt has surged by 94% since the previous quarter
Immunome's quick ratio has decreased by 37% YoY and by 34% QoQ
Key stats
What are the main financial stats of IMNM
Market
Valuations
Earnings
Shares outstanding
86.95M
Market cap
$740.82M
Enterprise value
$602.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.94
Price to sales (P/S)
55.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
66.6
Revenue
$9.04M
Gross profit
$9.04M
Operating income
-$305.8M
Net income
-$292.96M
EBIT
-$292.96M
EBITDA
-$290.86M
Free cash flow
-$117.97M
Per share
Balance sheet
Liquidity
EPS
-$5
EPS diluted
-$5
Free cash flow per share
-$2.01
Book value per share
$2.9
Revenue per share
$0.15
TBVPS
$4.1
Total assets
$240.24M
Total liabilities
$59.08M
Debt
$4.77M
Equity
$181.17M
Working capital
$167.03M
Debt to equity
0.03
Current ratio
4.08
Quick ratio
4
Net debt/EBITDA
0.48
Margins
Efficiency
Dividend
EBITDA margin
-3,217.1%
Gross margin
100%
Net margin
-3,240.4%
Operating margin
-3,382.4%
Return on assets
-105.3%
Return on equity
-125.3%
Return on invested capital
-520.5%
Return on capital employed
-157.6%
Return on sales
-3,240.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMNM stock price
How has the Immunome stock price performed over time
Intraday
0.24%
1 week
7.71%
1 month
4.54%
1 year
-40.29%
YTD
-19.77%
QTD
26.6%
Financial performance
How have Immunome's revenue and profit performed over time
Revenue
$9.04M
Gross profit
$9.04M
Operating income
-$305.8M
Net income
-$292.96M
Gross margin
100%
Net margin
-3,240.4%
Immunome's operating income has shrunk by 179% YoY but it has increased by 3.7% QoQ
IMNM's net income has dropped by 174% year-on-year but it is up by 4.1% since the previous quarter
Immunome's gross profit has decreased by 36% YoY and by 11% QoQ
The revenue fell by 36% YoY and by 11% QoQ
Growth
What is Immunome's growth rate over time
Valuation
What is Immunome stock price valuation
P/E
N/A
P/B
2.94
P/S
55.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
66.6
IMNM's EPS is up by 38% QoQ and by 7% YoY
The equity has soared by 51% YoY but it has contracted by 16% from the previous quarter
The price to book (P/B) is 39% lower than the 5-year quarterly average of 4.8 and 25% lower than the last 4 quarters average of 3.9
The revenue fell by 36% YoY and by 11% QoQ
IMNM's price to sales (P/S) is 32% lower than its last 4 quarters average of 80.8
Efficiency
How efficient is Immunome business performance
Immunome's ROE has soared by 56% YoY and by 10% from the previous quarter
The company's return on assets rose by 18% YoY and by 12% QoQ
The ROIC is up by 12% from the previous quarter
IMNM's ROS is down by 7% QoQ
Dividends
What is IMNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMNM.
Financial health
How did Immunome financials performed over time
Immunome's total liabilities has soared by 106% YoY and by 41% from the previous quarter
The total assets has soared by 62% YoY but it has contracted by 6% from the previous quarter
IMNM's debt is 97% smaller than its equity
Immunome's debt to equity has soared by 200% from the previous quarter and by 200% YoY
IMNM's debt has surged by 94% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.